For Melanoma, Pretreatment Influences Vemurafenib Therapy Outcomes
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that the type of pretreatment, such as chemotherapy or immunotherapy, greatly influences vemurafenib therapy outcomes for patients with BRAF V600 mutated melanoma.
For the mutlicenter, retrospective study, researchers sought to investigate the patterns associated with vemurafenib therapy outcomes and to identify any predictive factors of therapy response. Researchers identified 300 patients with BRAF V600 mutated stage 4 melanoma from 14 institutions. Patients had a median follow-up time of 13 months, a median progression-free survival of 5.1 months, and a median overall survival of 7.6 months.
Results showed that patients with a serum LDH ≤ULN (P = 0.0000001), an ECOG overall performance status of 0 (P = 0.00089), and BRAF V600E mutated disease (P = 0.016) had the best response under vemurafenib therapy. In addition, previous immunotherapy was associated with a positive impact on survival (HR = 0.57; P = 0.025), while prior chemotherapy (HR = 2.17; P = 0.039) and tyrosine kinase inhibitor therapy (HR = 1.86; P = 0.014) were associated with a negative impact.
Furthermore, the researchers found that elevated serum LDH (HR = 1.45; P = 0.012), age >55 years (HR = 0.72; P = 0.019), and gender (HR = 0.70; P = 0.039) are independent predictors of vemurafenib therapy outcomes.
Type of pretreatment greatly influences vemurafenib therapy outcomes for BRAF V600 mutated melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
- Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer